ALXN News and Press, Alexion Pharmaceuticals Inc. From 04/27/20

This past two months have been quite the emotional rollercoaster for investors. Since the benchmark S&P 500 hit an all-time record closing high on Feb. 19, 2020, we've witnessed: Beyond just breaking stock market records, we've also witnessed 22 million Americans lose their jobs in a four...

Alexion Pharmaceuticals (NASDAQ: ALXN) recently announced that it would initiate a phase 3 study to investigate the safety and efficacy of Ultomiris as a treatment for COVID-19. Ultomiris is already approved for the treatment of paroxysmal nocturnal hemoglobinuria, a rare blood disease that ...

Alexion Pharmaceuticals (NASDAQ: ALXN ) announces plans for a 270-subject Phase 3 clinical trial evaluating Ultomiris (ravulizumab-cwvz) in hospitalized COVID-19 patients with severe pneumonia or acute respiratory distress syndrome. More news on: Alexion Pharmaceuticals, Inc., Healthcare...

- Global study to enroll approximately 270 adults with COVID-19 and severe pneumonia or acute respiratory distress syndrome - - Company maintains commitment to supplying its medicines to patients for currently approved indications - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to...

BridgeBio ( BBIO ) is something of a holding company with a number of public and private biopharma companies under its hood. It has a very long pipeline of some 20 candidates, 3 of them in late stage development. Phase 3 data readouts are next year. This is a good thing because right now, du...

Last month, I published a list of Magic Formula stocks that all had $2.5bn or greater market cap. In this update, I intend to look into how certain companies or segments of that selection have performed and how the Magic Formula selection has changed. For those unfamiliar with the Magic Form...

I sure hope investors have their antacids handy, because it's been a bumpy ride for seven weeks and counting. The physical and financial toll being exacted by the spread of COVID-19 has created a stock market that's even more volatile than what we witnessed during the height of the financial cri...

There are plenty of promising biotech stocks for investors to sift through right now. One of these companies is Alexion Pharmaceuticals (NASDAQ: ALXN) , a developer of treatments for rare diseases that has seen tremendous success with its flagship drug, Soliris. With management expecting fur...

- Company Announces 2020 Annual Shareholder Meeting To Be Held Virtually - Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2020 before the US financial markets open on May 6, 2020. Fol...

The coronavirus outbreak and the effects of COVID-19 have gone deeper and wider than most people would have expected. That applies just as much to markets as anywhere. Whether it's a tech sector that is supporting our new work from home or re-rating as expensive EV/Sales multiples make less se...